The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
A randomised, double blind, placebo controlled trial with vitamin D 3 as an add on treatment to interferon β-1b in patients with multiple sclerosis
Abstract
OBJECTIVES: To study the safety and efficacy of vitamin D3 as an add on therapy to interferon β-1b (IFNB) in patients with multiple sclerosis (MS). METHODS: 1 year, double blind, placebo controlled, randomised study in 66 MS patients. The primary outcomes were T2 burden of disease (BOD) on MRI scans, proportion of patients with serum levels of 25-hydroxyvitamin D (25(OH)D) ≥85 nmol/l or intact parathyroid hormone (PTH) ≤20 ng/l, and number of adverse events. Secondary outcomes were number of MRI enhancing T1 lesions and new T2 lesions, annual relapse rate, changes in the Expanded Disability Status Scale score, timed 25 foot walk test and timed 10 foot tandem walk tests. RESULTS: Median change in BOD was 287 mm(3) in the placebo group and 83 mm(3) in the vitamin D group (p=0.105). Serum levels of 25(OH)D increased from a mean of 54 (range 19-82) nmol/l to 110 (range 67-163) nmol/l in the vitamin D group. 84% of patients reached a serum 25(OH)D level >85 nmol/l in the vitamin D group and 3% in the placebo group (p<0.0001). Patients in the vitamin D group showed fewer new T2 lesions (p=0.286) and a significantly lower number of T1 enhancing lesions (p=0.004), as well as a tendency to reduced disability accumulation (p=0.071) and to improved timed tandem walk (p=0.076). There were no significant differences in adverse events or in the annual relapse rate. CONCLUSION: Vitamin D3 add on treatment to IFNB reduces MRI disease activity in MS. TRIAL REGISTRATION NUMBER: EudraCT number 2007-001958-99 and ClinicalTrialsGov number NCT01339676.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Self-citationSerum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006) · JAMA · doi:10.1001/jama.296.23.2832 · Cited by 1,897
Diagnostic criteria for multiple sclerosis
Poser, C. M., & Brinar, V. V. (2001) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(00)00125-6 · Cited by 1,283
Vitamin D intake and incidence of multiple sclerosis
Munger, K. L., Zhang, S. M., O’Reilly, E., Hernán, M. A., Olek, M. J., Willett, W. C., & Ascherio, A. (2004) · Neurology · doi:10.1212/01.wnl.0000101723.79681.38 · Cited by 1,093
Cantorna, M. T., Hayes, C. E., & DeLuca, H. F. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7861 · Cited by 718
Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis
Simpson, S., Blizzard, L., Otahal, P., Van der Mei, I., & Taylor, B. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.240432 · Cited by 718
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study
van der Mei, I. A. F., Ponsonby, A.-L., Dwyer, T., Blizzard, L., Simmons, R., Taylor, B. V., Butzkueven, H., & Kilpatrick, T. (2003) · BMJ · doi:10.1136/bmj.327.7410.316 · Cited by 551
Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis
Simpson, S., Taylor, B., Blizzard, L., Ponsonby, A., Pittas, F., Tremlett, H., Dwyer, T., Gies, P., & van der Mei, I. (2010) · Annals of Neurology · doi:10.1002/ana.22043 · Cited by 457
A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis
Burton, J. M., Kimball, S., Vieth, R., Bar-Or, A., Dosch, H.-M., Cheung, R., Gagne, D., D'Souza, C., Ursell, M., & O'Connor, P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cec2 · Cited by 360
Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis
Smolders, J., Menheere, P., Kessels, A., Damoiseaux, J., & Hupperts, R. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508094399 · Cited by 340
Vitamin D status is associated with relapse rate in pediatric‐onset multiple sclerosis
Mowry, E. M., Krupp, L. B., Milazzo, M., Chabas, D., Strober, J. B., Belman, A. L., McDonald, J. C., Oksenberg, J. R., Bacchetti, P., & Waubant, E. (2010) · Annals of Neurology · doi:10.1002/ana.21972 · Cited by 329
The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
Kieseier, B. C. (2011) · CNS Drugs · doi:10.2165/11591110-000000000-00000 · Cited by 308
Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle
Kampman, M. T., Wilsgaard, T., & Mellgren, S. I. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0395-5 · Cited by 259
25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis
Soilu-Hänninen, M., Airas, L., Mononen, I., Heikkilä, A., Viljanen, M., & Hänninen, A. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1157oa · Cited by 236
Self-citationSafety of vitamin D3 in adults with multiple sclerosis
Kimball, S. M., Ursell, M. R., O’Connor, P., & Vieth, R. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.645 · Cited by 227
Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl, H., Toyka, K. V., Rieckmann, P., Gold, R., Hartung, H.-P., & Hohlfeld, R. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0061-1 · Cited by 212
Soilu-Hanninen, M., Laaksonen, M., Laitinen, I., Eralinna, J.-P., Lilius, E.-M., & Mononen, I. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.105320 · Cited by 206
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis
Stein, M. S., Liu, Y., Gray, O. M., Baker, J. E., Kolbe, S. C., Ditchfield, M. R., Egan, G. F., Mitchell, P. J., Harrison, L. C., Butzkueven, H., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182343274 · Cited by 185
Vitamin D: a natural inhibitor of multiple sclerosis
Hayes, C. E. (2000) · Proceedings of the Nutrition Society · doi:10.1017/s0029665100000768 · Cited by 180
Mechanisms underlying the effect of vitamin D on the immune system
Cantorna, M. T. (2010) · Proceedings of The Nutrition Society · doi:10.1017/s0029665110001722 · Cited by 170
Gestational vitamin D and the risk of multiple sclerosis in offspring
Mirzaei, F., Michels, K. B., Munger, K., O'Reilly, E., Chitnis, T., Forman, M. R., Giovannucci, E., Rosner, B., & Ascherio, A. (2011) · Annals of Neurology · doi:10.1002/ana.22456 · Cited by 158
Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment
Oliver, R., Clarkson, J., Conway, D. I., Glenny, A., Macluskey, M., Pavitt, S. H., Sloan, P., Panel, T. C. E., & Worthington, H. V. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006205.pub2 · Cited by 149
Sørensen, P. S., Lycke, J., Erälinna, J.-P., Edland, A., Wu, X., Frederiksen, J. L., Oturai, A. B., Malmeström, C., Stenager, E., Sellebjerg, F. T., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70144-2 · Cited by 119
Auer, D. P., Schumann, E. M., K�mpfel, T., G�ssl, C., & Trenkwalder, C. (2000) · Annals of Neurology · Cited by 107
Sumelahti, M., Tienari, P. J., Hakama, M., & Wikström, J. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.1.25 · Cited by 70
Self-citationSerum 25-hydroxyvitamin D and muscle atrophy in the elderly
Dawson-Hughes, B. F. (2011) · Proceedings of The Nutrition Society · doi:10.1017/s0029665111003260 · Cited by 64
Can vitamin D3 supplementation prevent bone loss in persons with MS? A placebo-controlled trial
Steffensen, L. H., Jørgensen, L., Straume, B., Mellgren, S. I., & Kampman, M. T. (2011) · Journal of Neurology · doi:10.1007/s00415-011-5980-6 · Cited by 54
Steffensen, L. H., Mellgren, S. I., & Kampman, M. T. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5337-6 · Cited by 49
Month of birth is associated with multiple sclerosis but not with HLA-DR15 in Finland
Saastamoinen, K., Auvinen, M., & Tienari, P. J. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511426814 · Cited by 39
Self-citationCombination therapy in MS—still a valid strategy
Kieseier, B. C., & Stüve, O. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.164 · Cited by 9
Khan (2000) · doi:10.1002/1531-8249(200008)48:2
Cited by
Prietl, B., Treiber, G., Pieber, T., & Amrein, K. (2013) · Nutrients · doi:10.3390/nu5072502 · Cited by 1,130
ESPEN guideline clinical nutrition in neurology
Burgos, R., Bretón, I., Cereda, E., Desport, J. C., Dziewas, R., Genton, L., Gomes, F., Jésus, P., Leischker, A., Muscaritoli, M., et al. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.09.003 · Cited by 571
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression
Ascherio, A., Munger, K. L., White, R., Köchert, K., Simon, K. C., Polman, C. H., Freedman, M. S., Hartung, H.-P., Miller, D. H., Montalbán, X., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5993 · Cited by 516
Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential
Dankers, W., Colin, E. M., van Hamburg, J. P., & Lubberts, E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00697 · Cited by 442
Vitamin D and Multiple Sclerosis: A Comprehensive Review
Sintzel, M. B., Rametta, M., & Reder, A. T. (2018) · Neurology and Therapy · doi:10.1007/s40120-017-0086-4 · Cited by 435
Metadata
- Authors
- Soilu-Hänninen, M., Åivo, J., Lindström, B.-M., Elovaara, I., Sumelahti, M.-L., Färkkilä, M., Tienari, P., Atula, S., Sarasoja, T., Herrala, L., Keskinarkaus, I., Kruger, J., Kallio, T., Rocca, M. A., & Filippi, M.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2012-02-22
- Volume
- 83
- Issue
- 5
- Pages
- 565-571
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- OpenAlex
- W2097284781
- Cited by
- 269
- References
- 31
- FWCI
- 23.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.